Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Child's Nervous System
Published in: Child's Nervous System 11/2017

01-11-2017 | Original Paper

Lacosamide treatment of childhood refractory focal epilepsy: the first reported side effect in paediatric patients

Authors: Edibe Pembegul Yildiz, Melis Ulak Ozkan, Gonca Bektas, Tuğçe Aksu Uzunhan, Nur Aydinli, Mine Caliskan, Meral Ozmen

Published in: Child's Nervous System | Issue 11/2017

Login to get access

Abstract

Purpose

Lacosamide (LCM) is an effective antiepileptic drug (AED) approved for the treatment of focal epilepsy in both children and adults. The aim of this observational study was to review our centre’s experience with LCM and to characterise its efficacy and tolerability as an adjunct therapy in children with refractory focal epilepsy.

Methods

We retrospectively reviewed the medical records of 12 paediatric patients who underwent treatment with LCM from January 2014 to December 2015. We recorded the treatment response at three time points: at 3 and 6 months after LCM therapy and at the final follow-up visit. Children showing seizure reduction ≥ 50% were considered responders.

Results

We included 12 patients (five boys), and their mean age was 13.8 years (range: 6.2–17.6 years) at the end of LCM treatment. The average length of follow-up after starting LCM was 23 months (11–37 months). Eight patients (66%) had > 50% reduction in seizures at the 3-month follow-up visit, and seven (58%) had > 50% reduction at the 6-month follow-up visit. Six patients (50%) maintained ≥ 50% reduction in seizures at the final follow-up visit. Two patients (16.6%) were seizure free at the 6-month and final follow-up visits. Common adverse side effects included dizziness, ataxia, nausea, and vomiting. Two patients developed status epilepticus (SE), one each at 3 and 11 days after the first LCM dose; they both discontinued treatment.

Conclusions

Our study points to the efficacy of LCM in a small paediatric group. Furthermore, it was important to report status epilepticus after LCM administration in the paediatric population for the first time.
Literature
1.
2.
Casas-Fernández C, Martínez-Bermejo A, Rufo-Campos M, Smeyers-Durá P, Herranz-Fernández JL, Ibáñez-Micó S et al (2012) Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain. Drugs R D 12(4):187–197CrossRefPubMedPubMedCentral
3.
Doty P, Hebert D, Mathy FX, Byrnes W, Zackheim J, Simontac- chi K (2013) Development of lacosamide for the treatment of partial-onset seizures. Ann N Y Acad Sci 1291:56–68CrossRefPubMedPubMedCentral
4.
Guilhoto LM, Loddenkemper T, Gooty VD, Rotenberg A, Takeoka M, Duffy FH et al (2011) Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol 44(6):414–419CrossRefPubMed
5.
Gavatha M, Ioannou I, Papavasiliou AS (2011) Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav 20(4):691–693CrossRefPubMed
6.
Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R (2012) Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur J Paediatr Neurol 16(1):15–19CrossRefPubMed
7.
Grosso S, Parisi P, Spalice A, Verrotti A, Balestri P (2014) Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. Eur J Paediatr Neurol 18(1):55–59CrossRefPubMed
8.
Kim JS, Kim H, Lim BC, Chae JH, Choi J, Kim KJ et al (2014) Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy. Brain and Development 36(6):510–515CrossRefPubMed
9.
Pasha I, Kamate M, Didagi SK (2014) Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy. Pediatr Neurol 51(4):509–514CrossRefPubMed
10.
Yorns WR Jr, Khurana DS, Carvalho KS, Hardison HH, Legido A, Valencia I. (2014) Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy. J Child Neurol 29(1): 23–27
11.
Verrotti A, Loiacono G, Pizzolorusso A, Parisi P, Bruni O, Luchetti A et al (2013) Lacosamide in pediatric and adult patients: comparison of efficacy and safety. Seizure 22(3):210–216CrossRefPubMed
12.
Rastogi RG, Ng YT (2012) Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study. J Child Neurol 27(4):492–495CrossRefPubMed
13.
Toupin JF, Lortie A, Major P, Diadori P, Vanasse M, Rossignol E et al (2015) Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study. Epileptic Disord 17(4):436–443PubMed
14.
Villanueva V, Lopez-Gomariz E, Lopez-Trigo J, Palau J, García M, Villarroya T et al (2012) Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav 23(3):298–304CrossRefPubMed
15.
Buck ML, Goodkin HP (2012) Use of lacosamide in children with refractory epilepsy. J Pediatr Pharmacol Ther 17:211–219PubMedPubMedCentral
16.
Papacostas SS (2015) Status epilepticus developing during lacosamide monotherapy. BMJ Case Rep 2015
Metadata
Title
Lacosamide treatment of childhood refractory focal epilepsy: the first reported side effect in paediatric patients
Authors
Edibe Pembegul Yildiz
Melis Ulak Ozkan
Gonca Bektas
Tuğçe Aksu Uzunhan
Nur Aydinli
Mine Caliskan
Meral Ozmen
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
Child's Nervous System / Issue 11/2017
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-017-3586-8

Other articles of this Issue 11/2017

Child's Nervous System 11/2017 Go to the issue

Author’s Reply

In reply to “Letter to the Editor: Fetal ventriculomegaly: Diagnosis, treatment, and future directions.”

Cover Editorial

Anatomy of cranial nerves in the first Turkish illustrated anatomy manuscript

Original Paper

Conversion of external ventricular drainage to ventriculo-peritoneal shunt: to change or not to change the proximal catheter?

Original Paper

A retrospective review of 34 cases of pediatric pituitary adenoma

Original Paper

X-ray vs. CT in identifying significant C-spine injuries in the pediatric population

Original Paper

LIN28A, a sensitive immunohistochemical marker for Embryonal Tumor with Multilayered Rosettes (ETMR), is also positive in a subset of Atypical Teratoid/Rhabdoid Tumor (AT/RT)